T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells
详细信息 查看全文
- 作者：Ilaria Marigo1 ; 11 ; ilaria.marigo@ioveneto.it" class="auth_mail" title="E-mail the corresponding author ; Serena Zilio2 ; Giacomo Desantis1 ; Bernhard Mlecnik3 ; 4 ; 5 ; Andrielly H.R. Agnellini2 ; Stefano Ugel6 ; Maria Stella Sasso2 ; Joseph E. Qualls7 ; Franz Kratochvill7 ; Paola Zanovello1 ; 2 ; Barbara Molon1 ; 10 ; Carola H. Ries8 ; Valeria Runza8 ; Sabine Hoves8 ; Amé ; lie M. Bilocq3 ; 4 ; 5 ; Gabriela Bindea3 ; 4 ; 5 ; Emilia M.C. Mazza9 ; Silvio Bicciato9 ; Jé ; rô ; me Galon3 ; 4 ; 5 ; Peter J. Murray7 ; peter.murray@stjude.org" class="auth_mail" title="E-mail the corresponding author ; Vincenzo Bronte6 ; vincenzo.bronte@univr.it" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：12 September 2016
- 年：2016
- 卷：30
- 期：3
- 页码：377-390
- 全文大小：3320 K
文摘
- •
Effective anti-tumor CD8+ T cell therapy requires expansion of Tip-DCs
- •
Tip-DC differentiation depends on the affinity between TCR and MHC-peptide complexes
- •
CD40/CD40L axis is necessary for tumor rejection mediated by CD8+ T cells
- •
Favoring Tip-DC function in tumor environment enhances ACT efficacy